Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 studyPaolo F. Caimi, Carmelo Carlo‐Stella, Brad S. Kahl et al.|Haematologica|2023Cited by 37
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 studyJuan Pablo Alderuccio, Paolo F. Caimi, Weiyun Z. Ai et al.|Blood Advances|2022Cited by 6
P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAPaolo F. Caimi, Carmelo Carlo‐Stella, Weiyun Z. Ai et al.|HemaSphere|2023Cited by 3